F. Hoffmann-La Roche Ltd: Roche has rapidly developed additional testing options to differentiate mutations in the Omicron SARS-CoV-2 variant

Roche subsidiary TIB Molbiol rapidly developed additional testing options to differentiate mutations in the Omicron SARS-CoV-2 variant, as they continue to offer new and accurate detection solutionsThree

Related Keywords

United States ,America ,Nathalie Meetz ,Karl Mahler ,Sabine Borngr ,Gerard Tobin ,Bruno Eschli ,Birgit Masjost ,Sileia Urech ,Loren Kalm ,Karsten Kleine ,Drug Administration ,Roche Group Media Relations ,Hoffmann ,Oche ,Apidly ,Eveloped ,Dditional ,Testing ,Options ,Differentiate ,Mutations ,Micron ,Cars ,Variant ,